Online Only Articles

Acute myeloid leukemia patients’ clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts

Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Seragnoli Institute of Hematology, Bologna University School of Medicine, Italy
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Department of Haematology, Peter MacCallum Cancer Center, Melbourne, VIC, Australia
Beatson West of Scotland Cancer Center, Gartnavel General Hospital, Glasgow, United Kingdom
Division of Hematology, Jewish General Hospital, McGill University, Montreal, QC, Canada
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Roche Innovation Center Basel, Roche Pharma Research and Early Development, Switzerland
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Department of Hematology, Asian Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
Department of Internal Medicine, Seoul National University School of Medicine, Seoul, South Korea
Roche Innovation Center Penzberg, Roche Pharma Research and Early Development, Germany
New York Medical College, Valhalla, NY, USA
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA
Hematology, Institut Paoli Calmettes, Marseilles, France
Princess Margaret Hospital, Toronto, ON, Canada
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Roche Innovation Center New York, Roche Pharma Research and Early Development, NY, USA
Vol. 101 No. 5 (2016): May, 2016 https://doi.org/10.3324/haematol.2015.139717